A protein clue in the fight against muscular dystrophy?
NCT ID NCT07745218
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This study looks at whether levels of a protein called HMGB1 are different in people with LAMA2-related muscular dystrophy, a condition that causes severe muscle weakness. Researchers will measure HMGB1 in blood and muscle samples already collected from about 25 patients. The goal is to understand if HMGB1 could be a target for future therapies, but this study itself does not test any treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If HMGB1 levels are linked to disease severity, this could pave the way for a new companion therapy for muscular dystrophies.
- What could go wrong
- This is an observational study, so it won't directly test any treatment. The findings may not lead to a therapy, and results from a small group may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LAMA2-MD (MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY, MDC1A) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Irccs Ospedale San Raffaele
RECRUITINGMilan, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.